Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of delivering stable topical drug compositions

a topical drug and composition technology, applied in the field of topical drug compositions, can solve the problems of inability to deliver by these known means, large molecules such as insulin, are not able to diffuse through the skin, and are typically only useful, and achieve the effects of convenient and pleasant administration routes, and desirable physical characteristics

Inactive Publication Date: 2006-06-15
TRANSDERMAL BIOTECHNOLOGY INC
View PDF20 Cites 110 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent describes a way to make a substance that can be applied to the skin to be absorbed through the skin. This substance is made up of a special fat called phosphatidylcholine, which helps to keep the substance stable at room temperature. The patent also describes a method for making a drug or other active ingredient that can be applied to the skin with the phosphatidylcholine substance. This helps to keep the drug or active ingredient stable and can be absorbed through the skin."

Problems solved by technology

While effective for their purpose, these systems have typically only been useful for transdermal delivery of relatively small molecules.
However, large molecules, such as insulin, are not able to diffuse through the skin and cannot be delivered by these known means.
While the delivery of large molecules such as insulin have been addressed, such systems do not address the storage and retention of the effectiveness of the drug to be delivered.
Such substances may not be stored or carried (without refrigeration) by the user.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0018] Stable insulin topical preparations were formulated by first preparing a base solution. A polyenylphosphatidylcholine material denoted NAT 8729 which contained 80.6% PPC-enriched phosphatidylcholine and 4.9% lysophosphatidylcholine was obtained from Rhône-Poulenc. NAT 8729 (45% w / w) was shaved and added to a mixture of polyglycol E200 (50% w / w) and polyglycol E400 (5% w / w) both obtained from Dow Corning. The base solution was then covered well and lightning mixed with a special disintegration head impeller slowly at 800 rpm with slight heat. The temperature did not go above 40° C. Typical mixing times were 5 hours. The final solution is a crystal clear, viscous amber solution with no sediments or separations.

[0019] Into this base solution (97.25% w / w) was then mixed a Dow Corning Fluid 190 (1.00% w / w) [a siloxylated polyether comprising dimethyl, methyl(propylpolyethylene oxide propylene oxide, acetate) siloxane]; a Dow Corning silicone fluid denoted 200-5 or 10 cst (1.00% w...

example 2

[0023] Stable insulin compositions were formulated by first preparing a base solution. Polyglycol E200 (PEG-200) (50% w / w) was weighed and polyglycol E400 (PEG-400) (5% w / w) was added to the same container to obtain the desired weight, (both obtained from Dow Corning). PEG-200 and PEG-400 were lightning mixed at 38-40° C. with IKA model RW20 using a disintegration head impeller slowly at 800 rpm (speed 1), yielding PEG-200 / PEG-400 solution. A PPC-enriched phosphatidylcholine material denoted NAT 8729 containing 80.6% PPC-enriched phosphatidylcholine and 4.9% lysophosphatidylcholine was obtained from Rhone-Poulenc. NAT 8729 (45% w / w) was shaved and added to PEG-200 / PEG-400 solution, covered and mixed, with temperature not exceeding 40° C., until a clear, viscous amber solution with no sediments or separations resulted. The mixing time was approximately five hours. An alternative mixture can be prepared by covering and mixing the solution overnight without heat for a 95-96% yield. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.

Description

PRIOR APPLICATION [0001] This application is a divisional application of U.S. patent application Ser. No. 10 / 749,914 filed Dec. 31, 2003, now pending, which claimed priority benefits under 35 U.S.C. §119(e) of U.S. Provisional Patent Application Ser. No. 60 / 437,279 filed Dec. 31, 2002; and which is a continuation in part of application Ser. No. 10 / 448,632 filed May 30, 2003, now pending, which claimed priority benefits under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 60 / 384,597, filed May 31, 2002.FIELD OF THE INVENTION [0002] The present invention relates to topical drug delivery compositions and methods of transdermal drug delivery. More specifically, the present invention relates to stable drug delivery compositions for topical administration. BACKGROUND OF THE INVENTION [0003] Topical drug delivery systems are known. These systems deliver drugs, therapeutic agents and other desired substances transdermally and may be designed to act locally at the point of appl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/127A61K31/56A61K38/28A61K38/00A61K38/095A61K38/22A61K38/23A61K38/27A61K47/20A61K47/22A61K47/24
CPCA61K9/0014A61K9/02A61K9/06A61K9/127A61K9/1277A61K31/56A61K38/22A61K38/23A61K38/27A61K38/28A61K47/10A61K47/24A61K38/095A61K38/56A61K38/02A61K38/24A61K38/31A61P17/00A61P5/06A61P3/10A61J3/07A61K47/14A61K47/22A61K47/34C07K14/62
Inventor PERRICONE, NICHOLAS V.POTINI, CHIM
Owner TRANSDERMAL BIOTECHNOLOGY INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com